Abliva: Q2’21: KL1333 Project Progressing - Redeye

Redeye is encouraged by the progress of KL1333 ahead of an expected major capital raise to fund the next pivotal step in clinical development.

Länk till analysen i sin helhet: https://www.redeye.se/research/819170/abliva-q221-kl1333-project-progressing?utm_source=finwire&utm_medium=RSS